KRAS and ovarian cancer: Both Grisham and Moujaber reported that for high-grade ovarian cancer, there is a loss rather than a gain of the BRAF and/or KRAS mutations, while low-grade ovarian cancers are predominantly characterized by these mutations [46,47].